AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open

per Zielinski, Christoph C, Pinto, Carmine
Publicat a ESMO Open (2016)

ESMO Open—Cancer Horizons and the future of oncology

per Zielinski, Christoph C
Publicat a ESMO Open (2016)

CSCO joins ESMO Open—Cancer Horizons

per Zielinski, Christoph C, Wu, Yi-Long
Publicat a ESMO Open (2016)

ESMO Open: news in breast cancer 2019

per Lambertini, Matteo
Publicat a ESMO Open (2020)

ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)

per Ohe, Yuichiro, Zielinski, Christoph
Publicat a ESMO Open (2017)

ESMO Open special series on new emerging targets in cancer immunotherapy

per Lambertini, Matteo
Publicat a ESMO Open (2020)

Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment

per Morgan, Gilberto, Preusser, Matthias, Zielinski, Christoph
Publicat a ESMO Open (2020)

One year of ESMO Open: Cancer Horizons—where are we going from here?

per Zielinski, Christoph
Publicat a ESMO Open (2017)

Plasmodesmata. A Not So Open-and-Shut Case

per Oparka, K. J., Roberts, A. G.
Publicat 2001

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy

per Preusser, Matthias
Publicat a ESMO Open (2019)

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion

per Burke, Patrick W, Hoelzer, Dieter, Park, Jae H, Schmiegelow, Kjeld, Douer, Dan
Publicat a ESMO Open (2020)

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

per Banerjee, Susana, Gonzalez-Martin, Antonio, Harter, Philipp, Lorusso, Domenica, Moore, Kathleen N, Oaknin, Ana, Ray-Coquard, Isabelle
Publicat a ESMO Open (2020)

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion

per Awada, Ahmad, Gligorov, Joseph, Jerusalem, Guy, Preusser, Matthias, Singer, Christian, Zielinski, Christoph
Publicat a ESMO Open (2019)

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series

per Lambertini, Matteo, Preusser, Matthias, Zielinski, Christoph C
Publicat a ESMO Open (2019)

Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]

per Lamarca, A., Foster, L., Satyadas, T., Siriwardena, A., Valle, J.W.
Publicat a ESMO Open (2021)

Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]

per Peleg Hasson, S., Brezis, M.R., Shachar, E., Shachar, S.S., Wolf, I., Sonnenblick, A.
Publicat a ESMO Open (2021)

Corrigendum to ‘Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study’: [ESMO Open Volume 5, Issue 6, 2020, e000985]

per Shi, L., Xu, C., Ma, Y., Ou, Q., Wu, X., Lu, S., Shao, Y., Guo, R., Kong, J.
Publicat a ESMO Open (2021)

Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue...

per Lee, R.J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., Aung, T., Banfill, K., Baxter, M., Boyce, H., Brearton, G., Copson, E., Dickens, E., Eastlake, L., Gomes, F., Hague, C., Harrison, M., Horsley, L., Huddar, P., Hudson, Z., Khan, S., Khan, U.T., Maynard, A., McKenzie, H., Palmer, D., Robinson, T., Rowe, M., Thomas, A., Tweedy, J., Sheehan, R., Stockdale, A., Weaver, J., Williams, S., Wilson, C., Zhou, C., Dive, C., Cooksley, T., Palmieri, C., Freitas, A., Armstrong, A.C.
Publicat a ESMO Open (2021)

A lei geral de proteção de dados e o open finance

per Holz, Carlos Eduardo
Publicat 2022

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO...

per Banna, G.L., Cortellini, A., Cortinovis, D.L., Tiseo, M., Aerts, J.G.J.V., Barbieri, F., Giusti, R., Bria, E., Grossi, F., Pizzutilo, P., Berardi, R., Morabito, A., Genova, C., Mazzoni, F., Di Noia, V., Signorelli, D., Gelibter, A., Macerelli, M., Rastelli, F., Chiari, R., Rocco, D., Gori, S., De Tursi, M., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Montrone, M., Citarella, F., Marco, R., Cantini, L., Nigro, O., D'Argento, E., Buti, S., Minuti, G., Landi, L., Guaitoli, G., Lo Russo, G., De Toma, A., Donisi, C., Friedlaender, A., De Giglio, A., Metro, G., Porzio, G., Ficorella, C., Addeo, A.
Publicat a ESMO Open (2021)